Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 avr. 2026 06h48 HE | Source: Research and Markets

Medulloblastoma Drugs Market Analysis and Growth Forecast 2026-2030 & 2035 by Drug Candidate, Product, Route of Administration, Distribution Channel, End-user and Region

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Medulloblastoma Drug Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights, covering...
02 avr. 2026 06h13 HE | Source: Research and Markets

Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035 - United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Pediatric Neuroblastoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a detailed analysis of...
02 avr. 2026 05h56 HE | Source: Research and Markets

Glioblastoma Multiforme (GBM) Treatment Market to Grow by $1.44 Billion During 2026-2030: Strategic Analysis of 23 Industry Players

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme (GBM) Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive...
01 avr. 2026 04h43 HE | Source: Research and Markets

Proleukin Market Research Report 2026-2035: Epidemiology, Pipeline Analysis, Industry Insights and More

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Proleukin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
31 mars 2026 11h09 HE | Source: Research and Markets

Capecitabine Market Outlook 2026-2030 Shows 9% CAGR as Innovations in Therapies and Homecare Treatment Adoption Accelerate Industry Growth

Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Capecitabine Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report details market characteristics, size, growth,...
31 mars 2026 08h30 HE | Source: Research and Markets

$4.26 Billion Brain Tumor Drugs Market 2026: Trends and Growth Outlook to 2030 & 2035

Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Brain Tumor Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The brain tumor drugs market has witnessed robust...
31 mars 2026 08h09 HE | Source: Research and Markets

Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry

Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global kidney cancer drugs market has shown...
30 mars 2026 08h00 HE | Source: Teva Pharmaceutical Industries Ltd

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar...
30 mars 2026 08h00 HE | Source: Teva Pharmaceutical Industries Ltd

Teva gagne du terrain dans le domaine des médicaments biosimilaires grâce à l’approbation accordée par la FDA pour PONLIMSI™ (dénosumab-adet) et à l’acceptation d’un double dossier pour un candidat biosimilaire à Xolair® (omalizumab)

Le médicament biosimilaire de Teva, PONLIMSI™, est désormais approuvé par la FDA pour toutes les indications du produit de référence, Prolia® (dénosumab), dans le cadre du traitement de diverses...
30 mars 2026 08h00 HE | Source: Teva Pharmaceutical Industries Ltd

Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)

Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen zugelassen.Tevas vorgeschlagener...

Page précédente

Page suivante